Generic Name and Formulations:
Methyl aminolevulinate 16.8%; crm.
Galderma Laboratories, Inc.
Indications for METVIXIA:
For treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratoses of the face and scalp in immunocompetent patients, in combination with Aktilite CL128 lamp red light illumination.
See literature. Surface of lesion should be prepared before applying. Use nitrile gloves. Apply a layer of cream about 1mm thick to lesion and surrounding 5mm of normal skin. Do not apply more than 1g (half tube) per treatment session. Cover area with occlusive, non-absorbent dressing for 3 hours. Multiple lesions may be treated during the same session. Remove occlusive dressing and clean area with saline and gauze. Position Aktilite CL128 lamp. Required illumination time: 7–10 minutes. Keep area covered and away from light for at least 48 hours after. Two treatment sessions one week apart should be administered. Assess lesion response 3 months after the last treatment session.
<18yrs: not recommended.
Cutaneous photosensitivity. Porphyrin, peanut, or almond oil allergy.
Do not apply to eyes, mucous membranes. Avoid exposure to sunlight or bright indoor light during the period prior to Aktilite red light treatment. If red light treatment cannot be administered, remove cream and protect skin from sunlight or intense light for two days. Coagulation defects. Pregnancy (Cat.C). Nursing mothers.
Additive photosensitivity possible with concomitant photosensitizing agents.
Erythema, pain, burning and discomfort, pruritus, scabbing, crusting and erosions, edema and exfoliation of skin.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry
- Medical Schools Phase Out Lectures as Education Shifts Outside the Classroom
- Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency